

Contents

1	Introduction	1
1.1	Background	1
1.2	Non-clinical Development	2
1.2.1	Pharmacology	2
1.2.2	Toxicology/Product Safety	3
1.2.3	Formulation Development	4
1.3	Pre-marketing Clinical Development	4
1.3.1	Phase I Clinical Trials	5
1.3.2	Phase II Clinical Trials	7
1.3.3	Phase III Clinical Trials	7
1.3.4	Clinical Development for Products Treating Life-Threatening Diseases	8
1.3.5	New Drug Application/Biologics License Application	10
1.4	Clinical Development Plan	10
1.5	Patient-Centered Outcomes	12
1.5.1	Clinical Outcome Assessments	12
1.5.2	Patient-Reported Outcomes	13
1.6	Post-marketing Clinical Development	15
1.7	Product Label	17
1.8	Importance of Phase II Clinical Development	19
1.9	Highlight of Each Chapter of This Book	22
	References	24
2	Concept of Alpha	27
2.1	Lady Tasting Tea	27
2.2	Alpha Type I Error Rate	30
2.3	Intention-to-Treat	32
2.4	Patient Analysis Sets	35

2.5	Multiple Comparisons	36
2.5.1	Multiple Doses	36
2.5.2	Multiple Endpoints	40
2.5.3	Other Types of Multiplicity	44
2.6	<i>P</i> -Value and Statistical Significance	46
2.7	Stages of a Clinical Trial	49
2.8	Subject Selection and Choice of Alpha at Phase II	51
	References	53
3	Confirmation and Exploration	55
3.1	Introduction	55
3.2	A Motivational Example	56
3.3	Clinical Development Plan (CDP)	57
3.4	Clinical Study Design and Sample Size Calculations	59
3.5	Statistical Analysis Plan (SAP)	60
3.6	Application Example—Another Three Group Phase III Design	61
3.7	Application Example—Dose Selection	62
3.8	Proof of Concept and Dose Ranging	64
3.9	Treatment-by-Factor Interaction	66
3.10	Evaluation of Product Safety	71
3.11	Every Clinical Trial Can Be Considered as Both Confirmatory and Exploratory	72
3.12	Conclusion	73
	References	74
4	Design a Proof of Concept Trial	75
4.1	Introduction	75
4.2	Proof of Concept Trials	77
4.2.1	Impact of PoC Decisions	77
4.2.2	How to Communicate Risks Associated with a PoC Study	79
4.3	The Primary Endpoint in a PoC Design	80
4.4	MTD Could Be Under Estimated or Over Estimated	81
4.5	Monotonicity Assumption	83
4.5.1	Background	83
4.5.2	Strong or Weak Application of the Monotonicity Assumption	84
4.5.3	Why This Assumption Is Still Useful	85
4.6	Agreement on a Delta	87
4.7	Choice of Alpha and Beta	89
4.8	Sample Size Considerations	90
	References	91

5	Design of Dose-Ranging Trials	93
5.1	Background	93
5.2	Finding Minimum Effective Dose (MinED)	95
5.3	A Motivating Example	97
5.4	How Wide a Range of Doses to Study?	97
5.4.1	Definition of Dose Range in a Given Study	99
5.4.2	Binary Dose Spacing	100
5.5	Frequency of Dosing	100
5.6	Parallel Controlled Fixed Dose Designs	102
5.7	Number of Doses and Control Groups	104
5.8	MCP-Mod.	105
5.9	Sample Size Considerations	107
5.10	Application Example	109
5.11	Discussion	113
	References	115
6	Combining Proof of Concept and Dose-Ranging Trials	117
6.1	Background	117
6.2	Considerations in Designing Combined PoC and Dose Ranging Studies	118
6.3	Concerns of Using a Dose-Response Model	119
6.4	Sample Size Allocation	121
6.4.1	Comparison of Power	123
6.5	Estimation of Dose-Response Relationship	126
6.6	Risk of Inconclusiveness	128
	References	129
7	Risks of Inconclusiveness	131
7.1	Introduction	131
7.2	Go/NoGo Decision in a Two-Group PoC Study	132
7.2.1	The Decision Process	136
7.2.2	The Concept of Another Delta	136
7.3	Go/NoGo Decision with Multiple Treatment Groups	137
7.4	Dose Titration Studies Cannot Be Used for Dose-Finding	139
7.5	A Practical Design to Help Finding MinED	140
7.6	Discussion	142
	References	143
8	Analysis of a Proof of Concept Study	145
8.1	Introduction	145
8.2	When the Primary Endpoint Is a Continuous Variable	146
8.2.1	Data Description and Hypothesis	146
8.2.2	T-Test Approach	147
8.2.3	Analysis of Covariance Approach	148
8.2.4	Mixed-Effect Models to Analyze the Longitudinal Data	149

8.3	When the Primary Endpoint Is a Binary Variable.	151
8.3.1	Data Description and Hypothesis.	151
8.3.2	Cochran-Mantel-Haenszel Method.	151
8.3.3	Logistic Regression.	152
8.4	Discussion.	153
	References.	154
9	Data Analysis for Dose-Ranging Trials	
	with Continuous Outcome	155
9.1	Introduction	155
9.2	Data and Preliminary Analysis	157
9.3	Establishing PoC with a Trend Test	158
9.4	Multiple Comparison Procedure (MCP) Approach	160
9.4.1	Fisher's Protected LSD (Fixed Sequence Test)	161
9.4.2	Bonferroni Correction	162
9.4.3	Dunnett's Test.	163
9.4.4	Holm's Step-Down Procedure	164
9.4.5	Hochberg Step-Up Procedure.	165
9.4.6	Gate-Keeping Procedure	166
9.5	Modeling Approach (Mod).	167
9.5.1	Dose-Response Models	167
9.5.2	R Step-by-Step Implementations	169
9.6	MCP-Mod Approach	173
9.6.1	Introduction.	173
9.6.2	Step-by-Step Implementations in R Package "MCPMod".	175
9.7	Discussion.	180
	References.	181
10	Data Analysis of Dose-Ranging Trials for Binary Outcomes	183
10.1	Introduction	183
10.2	Data and Preliminary Analysis	184
10.3	Modeling Approach	187
10.3.1	Pearson's χ^2 -Test.	187
10.3.2	Cochran-Armitage Test for Trend	189
10.3.3	Logistic Regression with Dose as Continuous Variable.	190
10.3.4	Logistic Regression with Dose as Categorical Variable.	192
10.4	Multiple Comparisons.	193
10.4.1	The Raw p -Values.	193
10.4.2	Bonferroni Adjustment	194
10.4.3	Bonferroni-Holm Procedure	195
10.4.4	Hochberg Procedure	197

10.4.5	Gatekeeping Procedure	198
10.4.6	MCP Using p -Values from Cochran-Mantel-Haenszel Test	199
10.5	Discussion.	203
	References.	204
11	Bayesian Approach	205
11.1	Introduction	205
11.1.1	An Example on Bayesian Concept	205
11.1.2	A Brief History	206
11.1.3	Bayes Theorem	206
11.1.4	Bayesian Hypothesis Testing Framework	207
11.2	Bayesian Updating	208
11.2.1	Example Continued for Bayesian Updating	208
11.3	Bayesian Inference	212
11.4	Markov Chain Monte Carlo (MCMC) Method	214
11.5	Bayesian Methods for Phase II Clinical Trials	216
11.6	Example	217
11.6.1	Using Non-informative Priors	218
11.6.2	Using Informative Priors	220
11.6.3	Summary	222
	References.	223
12	Overview of Phase III Clinical Trials	225
12.1	Introduction	225
12.2	Scope of Phase III Plans	225
12.3	Drug Label and Target Product Profile	226
12.4	Phase III Non-inferiority Trial Designs	227
12.5	Dose and Regimen Selection, Drug Formulation and Patient Populations	228
12.5.1	Dose and Regimen Selection	228
12.5.2	Drug Formulations	230
12.5.3	Patient Populations	231
12.6	Number of Phase III Trials for a Labeling Claim	231
12.7	Number of Primary Efficacy Endpoints	232
12.8	Missing Data Issues	233
12.9	Phase III Clinical Outcome Assessments	234
12.10	Multi-regional Phase III Clinical Trial Issues	237
12.11	The Trend Towards Personalized or Precision Medicines	238
12.12	Summary	239
	References.	239

Phase II Clinical Development of New Drugs

Ting, N.; Chen, D.-G.; Ho, S.; Cappelleri, J.

2017, XVII, 241 p. 25 illus., 17 illus. in color., Hardcover

ISBN: 978-981-10-4192-1